Overview: • Under the radar companies • Huge upside • Difficult FDA approval behind them ⇒ Typical for drug device combo ⇒ 2 CRLs • But...

Overview: • One of my favorite under the radar companies • Huge upside • Difficult FDA approval behind them   ⇒ Typical for drug device combo   ⇒ 2 CRLs • But still high risk/high reward stock Details: Single drug company • Furoscix   ⇒ SubQ furosemide via on body infusor   ⇒ Diuretic for fluid build up in chronic heart failure • Early commercial - Launched Feb ‘23 • Market opp $7B Sales Pitch: Large cost savings for Medicare & insurers ✔️Patients stay home instead of IV @ ho

Presentations at 62nd American Society of Hematology Annual Meeting